MIDAS (Modafinil in Debilitating Fatigue After Stroke) [Clinical Sciences]

Conclusions—Stroke survivors with nonresolving fatigue reported reduced fatigue and improved quality of life after taking 200 mg daily treatment with modafinil.Clinical Trial Registration—URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368268. Unique identifier: ACTRN12615000350527.

Source: Stroke - April 24, 2017 Category: Neurology Authors: Andrew Bivard, Thomas Lillicrap, Venkatesh Krishnamurthy, Elizabeth Holliday, John Attia, Heather Pagram, Michael Nilsson, Mark Parsons, Christopher R. Levi Tags: Clinical Studies, Ischemic Stroke Original Contributions Source Type: research